United States Biotechnology & Medical Research

Polaryx Therapeutics, Inc (PLYX)

Polaryx Therapeutics witnessed notable insider activity recently, highlighted by CEO Yang Alex Keun Mo acquiring shares valued at approximately $360,003. This purchase occurred shortly before the company reported a significant miss in its latest earnings report. Despite a 37.1% decline in stock price over the past ninety days, leadership maintains a singular focus on accumulation.

No insider activity signal

Not featured in screeners

Featured in screeners

No insider activity signal

Not featured in screeners

Ticker: PLYX Exchange: NAS

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings

Insider activity signals

0 activity signals detected for Polaryx Therapeutics, Inc

No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders

Company data & Insiders

Subscribe to get access to the company description and key fundamental data (market cap, shares outstanding, dividend yield, % of shares held by insiders and more)

Download results Settings

Trades

Yang Alex Keun Mo Chief Executive Officer Executive Director Large shareholder

Transaction date 27 May 2026

Purchase

Price

315.04

Quantity 79,569 -7.4%

Value US$3,003,164

Comments Filing

2.3

Landis G. Michael Chief Financial Officer Executive Director

Transaction date 18 Feb 2026

Purchase

Price

336.40

Quantity 79,017 +47.6%

Value US$862,850

Notification date	Transaction date	B/S Transaction type	Insider and/or position	Nb. shares Price Value	Number of shares	Price	Value	Details
2026-05-28	2026-05-27	B Purchase	Yang Alex Keun Mo Chief Executive Officer Executive Director Large shareholder	79,569 -7.4% 315.04 US$3,003,164	79,569 -7.4%	315.04	US$3,003,164
2026-02-20	2026-02-18	B Purchase	2.3 Landis G. Michael Chief Financial Officer Executive Director	79,017 +47.6% 336.40 US$862,850	79,017 +47.6%	336.40	US$862,850